Aldeyra Therapeutics' RASP Modulator Shows Improved Signs of Alcohol Intoxication

Aldeyra Therapeutics Inc ALDX announced a demonstration of target engagement and improvement in the signs of alcohol intoxication in the Phase 2 trial of ADX-629.
Relative to the placebo, ADX-629 reduced dermal flushing, increased Romberg test balance time, and lowered ethanol RASP metabolite acetaldehyde levels following acute alcohol exposure.
ADX-629 and placebo were well tolerated, and no safety concerns were noted.
Related: Aldeyra's ADX-2191 Aces Late-Stage Study In Rare Vision Disorder.
In addition to the statistical superiority of ADX-629 over the placebo in Romberg test balance time, flushing, and acetaldehyde, total cholesterol, and LDL levels were statistically lower following ADX-629 treatment than following placebo treatment.
Aldeyra plans to initiate a Phase 2 trial of ADX-629 in moderate alcoholic hepatitis in 2023. Results from a Phase 2 trial of ADX-629 in chronic cough are expected in 1H of 2023, and results from Phase 2 clinical trials of ADX-629 in minimal change disease and Sjögren-Larsson Syndrome are expected in 2023.
Price Action: ALDX shares are up 0.96% at $6.28 on the last check Tuesday.
Photo Via Company